Recro Pharma, Inc. (NASDAQ:REPH) major shareholder Stonepine Capital Management, sold 510,000 shares of the firm’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $7.40, for a total value of $3,774,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Stonepine Capital Management, also recently made the following trade(s):
- On Thursday, May 11th, Stonepine Capital Management, sold 244,629 shares of Recro Pharma stock. The shares were sold at an average price of $7.65, for a total value of $1,871,411.85.
- On Thursday, May 4th, Stonepine Capital Management, sold 217,308 shares of Recro Pharma stock. The shares were sold at an average price of $7.70, for a total value of $1,673,271.60.
Shares of Recro Pharma, Inc. (NASDAQ REPH) traded up 1.61% during midday trading on Friday, reaching $6.30. The company had a trading volume of 137,629 shares. Recro Pharma, Inc. has a 1-year low of $5.81 and a 1-year high of $12.50. The stock’s market capitalization is $120.02 million. The company’s 50-day moving average is $7.62 and its 200-day moving average is $7.69.
Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings data on Thursday, May 11th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.15. The company had revenue of $18.74 million during the quarter, compared to analysts’ expectations of $15.58 million. Recro Pharma had a negative return on equity of 61.09% and a negative net margin of 45.15%. On average, equities research analysts forecast that Recro Pharma, Inc. will post ($2.35) EPS for the current year.
Several equities research analysts have recently issued reports on the company. Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $9.50 target price for the company in a research report on Wednesday, May 17th. Aegis reaffirmed a “buy” rating and set a $11.00 target price on shares of Recro Pharma in a research report on Monday, March 27th. Roth Capital set a $20.00 target price on Recro Pharma and gave the company a “buy” rating in a research report on Saturday, May 13th. Finally, Janney Montgomery Scott lowered Recro Pharma from a “buy” rating to a “fair value” rating and decreased their target price for the company from $21.00 to $6.50 in a research report on Wednesday. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $14.14.
A number of hedge funds have recently bought and sold shares of REPH. Janney Montgomery Scott LLC boosted its stake in Recro Pharma by 17.8% in the first quarter. Janney Montgomery Scott LLC now owns 12,485 shares of the specialty pharmaceutical company’s stock worth $109,000 after buying an additional 1,885 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Recro Pharma during the fourth quarter worth approximately $118,000. Acadian Asset Management LLC purchased a new stake in Recro Pharma during the first quarter worth approximately $150,000. Wells Fargo & Company MN boosted its stake in Recro Pharma by 3.0% in the first quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock worth $150,000 after buying an additional 500 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in Recro Pharma during the first quarter worth approximately $156,000. Institutional investors own 64.19% of the company’s stock.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.